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ABSTRACT
Background We aimed to synthesise qualitative studies 
exploring medication- related experiences of polypharmacy 
among patients with multimorbidity.
Methods We systematically searched PubMed, Embase 
and Cumulative Index to Nursing and Allied Health 
Literature in February 2020 for primary, peer- reviewed 
qualitative studies about multimorbid patients’ medication- 
related experiences with polypharmacy, defined as the 
use of four or more medications. Identified studies were 
appraised for methodological quality by applying the 
Critical Appraisal Skills Programme checklist for qualitative 
research, and data were extracted and synthesised by the 
meta- aggregation approach.
Results We included 13 qualitative studies, representing 
499 patients with polypharmacy and a wide range 
of chronic conditions. Overall, most Critical Appraisal 
Skills Programme items were reported in the studies. 
We extracted 140 findings, synthesised these into 17 
categories, and developed five interrelated syntheses: 
(1) patients with polypharmacy are a heterogeneous 
group in terms of needing and appraising medication 
information; (2) patients are aware of the importance 
of medication adherence, but it is difficult to achieve; 
(3) decision- making about medications is complex; (4) 
multiple relational factors affect communication between 
patients and physicians, and these factors can prevent 
patients from disclosing important information; and (5) 
polypharmacy affects patients’ lives and self- perception, 
and challenges with polypharmacy are not limited to 
practical issues of medication- taking.
Discussion Polypharmacy poses many challenges to 
patients, which have a negative impact on quality of life 
and adherence. Thus, when dealing with polypharmacy 
patients, it is crucial that healthcare professionals 
actively solicit individual patients’ perspectives on 
challenges related to polypharmacy. Based on the reported 
experiences, we recommend that healthcare professionals 
upscale communicative efforts and involve patients’ 
social network on an individualised basis to facilitate 
shared decision- making and treatment adherence in 
multimorbidpatients with polypharmacy.
INTRODUCTION
Patients with multimorbidity often have 
complex treatment regimens requiring them 
to take several medications concurrently, 
a phenomenon termed polypharmacy.1 
Although a wide range of definitions exist for 
polypharmacy, a common definition is simul-
taneous use of five or more medications.2 
Polypharmacy is often clinically appropriate 
and is thus not necessarily a sign of inappro-
priate care,3 but the use of multiple medica-
tions in the elderly is associated with increases 
in mortality, adverse drug events, falls, length 
of hospital stay, and readmission rates.2 In 
addition, a high frequency of medication 
errors has been reported among primary care 
patients with polypharmacy,4 5 and discrepan-
cies often exist between medication lists in the 
primary and secondary healthcare sectors.5–7 
A 2018 systematic review found that 26 of 33 
studies examining patient- related risk factors 
for medication errors reported positive asso-
ciations between polypharmacy and medica-
tion errors.8
High rates of non- adherence have been 
identified among newly discharged patients 
with polypharmacy, and an increased 
number of medications prescribed in hospi-
tals is associated with non- adherence.9 In 
general, medication- related burden and 
patient experiences of medications nega-
tively affect patients’ health and well- being, 
as well as their medication- related beliefs and 
behaviours.10 This can lead to non- adherence, 
poorer therapeutic outcomes, and patients 
independently altering their medications 
or continuing treatment, which negatively 
Strengths and limitations of this study
 ► We employed a stringent process of selecting and 
appraising studies.
 ► The credibility of our results is enhanced by triangu-
lation of findings from different studies.
 ► The transferability of our findings to all patients tak-
ing more than four medications is unknown.
 ► A single author completed data extraction, potential-
ly limiting the confirmability of our study.
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affects their well- being.10 Multiple studies demonstrate 
that most patients are interested in having one or more 
medications deprescribed if possible.11–17
Increasing numbers of people live with multimorbidity 
and require multiple medications, and an investiga-
tion of their experiences is essential to understand the 
phenomenon of polypharmacy. In addition, it is uncer-
tain whether interventions to improve appropriate poly-
pharmacy have clinically significant effects.18 Insight into 
medication- related experiences, defined as the sum of 
events involving drug therapy that a patient has in their 
lifetime,19 of multimorbid patients with polypharmacy 
can help identify opportunities to improve care, develop 
effective interventions and align research with what 
matters most to patients. The aim of this study was to 
explore medication- related experiences of polypharmacy 
among patients with multimorbidity through a systematic 
review of qualitative studies.
METHODS
We conducted a preplanned structured search of qual-
itative studies exploring medication- related experi-
ences among multimorbid patients with polypharmacy. 
Although many studies defined polypharmacy as five or 
more medications, some defined it as four or more medi-
cations.2 To reflect varying definitions and capture all 
relevant studies, we used the latter definition. A system-
atic review of qualitative studies is ideal for our purpose 
because it provides an overview and reinterpretation of 
existing evidence from qualitative research.20
Search strategy
We identified search terms relevant to the three major 
concepts of our study aim: patient experiences, poly-
pharmacy and qualitative research. Synonyms and search 
terms were identified by reviewing the protocol for a 
previous review of qualitative studies on medication- 
related burden (not focused on patients with polyphar-
macy),10 as well as other qualitative review protocols. We 
also conducted a simple search in the PubMed database 
to identify relevant terms and medical subject headings. 
We applied the search strategy to PubMed, Embase and 
Cumulative Index to Nursing and Allied Health Litera-
ture (CINAHL) in February 2020 (online supplementary 
table 1). Searching PubMed and CINAHL in combina-
tion is recommended for identifying qualitative studies.21 
We modified the search strategy to specific database 
requirements, tailoring the use of indexing terms or 
symbols for wildcards. Search filters were not applied. We 
also screened the reference lists of included studies and 
relevant systematic reviews for additional studies. Finally, 
we removed duplicate references.
To be eligible for inclusion, studies had to (1) be peer- 
reviewed research concerning medication- related expe-
riences; (2) include patients with multimorbidity and 
polypharmacy aged 18 years or older taking four or more 
medications; (3) use a qualitative methodology; (4) be 
reported in English (or Danish, Swedish or Norwegian 
for practical reasons); and (5) be published from 1988 
onwards to ensure contemporary data. We excluded 
intervention studies. We first screened titles and abstracts 
and included studies related to both polypharmacy and 
multimorbidity. However, during subsequent full- text 
screening, we excluded studies that did not specifically 
address polypharmacy or studies focusing on patients 
with a single disease (n=9) or patients in palliative care 
(n=1) as they are unlikely to reflect the experiences in 
relation to multimorbidity and polypharmacy in the 
broader population. Two authors independently carried 
out both rounds of screening and resolved any disagree-
ments by consensus.
For articles that did not clarify whether patients 
took four or more medications, we contacted the 
corresponding author; one study was excluded after 
we received no reply. We used Covidence system-
atic review software (Melbourne, Australia). The 
Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses flow diagram was used for reporting the 
study selection process.22
Assessment of methodological quality
We assessed the methodological quality of the included 
studies with the Critical Appraisal Skills Programme 
(CASP) qualitative checklist, designed to help researchers 
make sense of qualitative research in a systematic way.23 
The 10- item checklist considers the validity of the results, 
the findings and their value in local settings.23 Two authors 
applied the checklist to included studies and resolved 
disagreements by consensus. No studies were excluded 
based on methodological quality.
Data extraction
We extracted data from each included study on authors, 
year, title, aim, study design, context, participants and 
analytical approach. Each finding, defined as the authors’ 
interpretation of their results,24 was identified and coded 
by a single author and entered into a spreadsheet (Micro-
soft Excel, Redmond, Washington, USA) for all studies. 
If studies included other views than those of polyphar-
macy patients, only the data relating to patients’ views 
were included in the synthesis. Using the terminology 
employed in the Joanna Briggs Institute Reviewer’s 
Manual, each finding was assigned a level of credibility 
based on illustrations in the form of supporting quota-
tions or field observations.24 Possible credibility levels 
were unequivocal (the illustration supported the finding 
beyond a reasonable doubt), credible (some association 
was present between the illustration and the finding, but 
it did not clearly support it, meaning that the finding was 
open to challenge) and unsupported (no illustration was 
presented). The credibility levels were assigned by CUE.
Data synthesis
We used meta- aggregation to synthesise the data.24 In 
this process, findings as expressed by researchers are 
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summarised to produce generalisations that provide a 
basis for identifying recommendations for action.25 All 
findings are linked to a specific category and then to a 
specific synthesis, providing transparency in reporting. 
The endpoint of meta- aggregation is the formation of 
concrete recommendations for practice and research, 
increasing the practical utility of the synthesis. Specif-
ically, the process of meta- aggregation includes three 
steps: (1) extracting all findings from the included arti-
cles, (2) developing categories of similar findings and (3) 
developing synthesised findings from at least two catego-
ries.25 Two authors, CUE and JTL, collaboratively derived 
categories and syntheses by inductively grouping similar 
findings and subsequently identifying conceptual cate-
gories. All syntheses, as well as the recommendations for 
practice and research that were subsequently developed, 
were discussed with all authors.
We report the data synthesis using the ENTREQ 
(Enhancing Transparency in Reporting the Synthesis 
of Qualitative Research) statement,26 an example of 
meta- aggregation,25 and the Joanna Briggs Institute 
Reviewer’s Manual.27
Patient and public involvement
Neither patients nor the public were involved in the 
research process.
RESULTS
Study inclusion
The search strategy yielded 1676 citations (figure 1); 1305 
remained after we removed duplicates and applied publi-
cation data and language restrictions. After screening 
titles and abstracts, we included 69 studies, of which 10 
met the eligibility criteria after full- text screening. The 
Figure 1 PRISMA flow diagram providing an overview of the selection process. CINAHL, Cumulative Index to Nursing and 
Allied Health Literature; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta- Analyses.
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primary reasons for exclusion during full- text screening 
were study populations that were not limited to patients 
with polypharmacy (n=18) and focus on a population 
with a specific disease (n=9) or palliative care patients 
(n=1). We identified three additional studies from refer-
ence lists, thus assessing a total of 13 studies for method-
ological quality and including them in the synthesis.28–40 
All studies were reported in the English language. See 
online supplementary table 2 for a list of studies excluded 
during full- text screening.
Study characteristics
Eleven studies used semistructured individual and/
or focus group interviews, and two studies applied an 
unstructured approach to conducting individual inter-
views. Patients were recruited from primary care and 
community settings. A total of 499 patients taking four 
or more medications for varying chronic conditions were 
included, the majority of whom were over the age of 65 
years and residing in communities. Five studies took place 
in the USA, three in the UK, three in Sweden, and one 
each in Australia and Germany (table 1).
Methodological quality
All 13 studies reported at least 8 of the 10 CASP check-
list items. No studies met the criteria of adequately 
considering the relationship between researchers and 
participants, and only two studies31 36 failed to report 
the information required by all remaining CASP items 
(table 2).
Synthesis
We extracted 140 findings from the 13 studies, grouping 
them into 17 categories describing a wide variety of 
patient experiences of polypharmacy (online supple-
mentary tables 3–7). We subsequently summarised 
the 17 categories into five interrelated syntheses 
describing central aspects of medication- related expe-
riences of patients with polypharmacy (figure 2). For 
additional data supporting the syntheses, see online 
supplementary table 8.
Synthesis 1: patients with polypharmacy are a heterogeneous 
group in terms of needing and appraising medication information
Even though it is generally difficult for patients with 
polypharmacy to understand information about harms 
and benefits of medications, patients with polyphar-
macy are a heterogeneous group in terms of needing 
and appraising information and respond differently 
to the same information. These differing needs for 
and ways of responding to information are illustrated 
by Krska and colleagues31 :
More than half the participants felt they needed infor-
mation to allay their concerns, beyond that provided 
directly by health professionals, which they obtained 
by various means, including books, patient informa-
tion leaflets (PILs) and the internet. Conversely, four 
participants either did not want to know about their 
medicines or would never seek further information. 
One was uncertain about the usefulness of PILs and 
three considered that information caused or wors-
ened rather than allayed concerns, meaning further 
reassurance and clarification from a health profes-
sional was needed.
Synthesis 2: patients are aware of the importance of medication 
adherence, but it is difficult to achieve
Patients are aware of the importance of adherence 
and of developing routines for taking medications. 
However, doing so requires substantial effort due 
to practical issues, regimen changes, and skipping, 
altering or forgetting doses, which may occur when 
patients assign different priorities to medications. 
Health professionals and patients’ social networks can 
facilitate medication adherence. Some of the chal-
lenges to maintaining medication routines are illus-
trated by Krska and colleagues31 :
Although all participants had developed routines 
for using medicines, which had become automatic 
or ‘second nature’ – ‘you think nothing of it’ – in-
terviews revealed the extent of the physical and or-
ganisational effort required by some patients in using 
medicines. … The impact of changes in daily routine 
sometimes resulted in medicines not being used.
Synthesis 3: decision-making about medications is complex
Generally, patients want to take fewer medications. A 
multitude of factors affect patients’ decision- making 
about medications, but physical function and the pref-
erence for a stable regimen are central. The desire 
for a stable regimen can even impact patients’ will-
ingness to discuss deprescribing. The following quota-
tion from a participant in the study by Linsky and 
colleagues32 illustrates the importance to patients of 
a stable regimen:
Oh, let’s give it a time frame and find out how it goes. 
I’m not going to quit it completely because I already 
seen where my blood pressure was up there and some-
times I felt weird because I didn’t even know what it 
was, and it was the high blood pressure. But if they 
are going to do something like that, well, if you want 
to do it on a trial basis and monitor me, fine, but right 
now it’s got everything working fine. I’m not going to 
fool with something that’s working good.
Synthesis 4: multiple relational factors affect communication 
between patients and physicians, and these factors can prevent 
patients from disclosing important information
Multiple factors in relationships between patients and 
healthcare professionals, such as unequal power rela-
tions, trust or lack thereof, problems in interacting with 
providers or in receiving care, and conflicting advice, 
affect communication and increase the risk that patients 
will not disclose important information about their 
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medication regimens. Continuity of care is important. 
Making changes to regimens without consulting 
prescribers beforehand is expressed in the following 
interpretation by Elliot and colleagues28 :
Experimenting with regimens ranged from stopping 
a medicine altogether; taking regular breaks; discon-
tinuing medicines to check if they are working, or to 
determine the cause of side effects, trying individual 
medicines in a complex new regimen; and reducing 
doses. One patient reported stopping taking their an-
tihypertensives to increase symptoms before a consul-
tation. Prescribers were often not consulted before 
interviewees changed regimens.
Synthesis 5: polypharmacy affects patients’ lives and self-
perception, and challenges with polypharmacy are not limited to 
practical issues
The burden of polypharmacy does not arise solely from 
logistical challenges of organising medications and 
routines. Polypharmacy affects the self- perception of 
patients, can be seen by patients as embarrassing, and 
causes adverse effects that can have grave implications 
for patients’ lives and affect their attitudes towards medi-
cations. The effect of taking multiple medications on 
patients’ self- perception is illustrated by Vandermause 
and colleagues39 :
Participants did not want to fall into the category of 
‘taking multiple medicines.’ Many rejected this de-
scriptor, though they fit the criterion of taking five 
or more medicines. No matter what their medicines, 
they did not want to be seen as medication users. The 
desire to be viewed outside this designation was com-
monly strong. It was not uncommon to hear stories of 
confusion and dejection when participants described 
medicine side effects or compatibility problems, bar-
riers to getting their prescriptions filled, and cost fac-
tors that were worrisome. All of these impediments 
affected their sense of who they were as persons. Their 
bodies were failing them, unless they could find a way 
to manage the problems they encountered.
Proposed implications
Based on the five syntheses, we proposed the following 
implications for practice:
 ► Healthcare professionals should actively solicit indi-
vidual patients’ perspectives on challenges related to 
polypharmacy (syntheses 1–5).
 ► Healthcare professionals should consider upscaling 
their communicative efforts to better inform and 
involve polypharmacy patients on their medications 
to an extent that reflects their needs (syntheses 1–5).
 ► Healthcare professionals should consider supporting 
patients with polypharmacy, preferably by involving 
patients’ social network, by coordinating and ensuring 
continuity of care, as well as to facilitate dealing with A
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practical and psychological issues with taking many 
medications (syntheses 2, 4 and 5).
In addition, we propose the following recommenda-
tions for strengthening research in medication- related 
experiences of multimorbid patients with polypharmacy:
 ► Studies of the different medication information needs 
of patients with polypharmacy should be conducted 
(synthesis 1).
 ► Interventions promoting continuity of care should be 
evaluated qualitatively to assess patients’ perspectives 
on polypharmacy (synthesis 4).
DISCUSSION
To the best of our knowledge, this is the first systematic 
review of qualitative studies to comprehensively compile 
medication- related experiences of multimorbid patients 
with polypharmacy. From the 13 included studies, we 
extracted a plethora of experiences of being a patient 
with polypharmacy and formed five interrelated syntheses 
related to the differing medication information needs, 
the difficulties of achieving adherence, the complexity 
of decision- making, the relationship between healthcare 
professionals and patients, and the impact on patients’ 
self- perception. These formed the basis for several 
recommendations that can improve care for patients 
with polypharmacy, as well as guide future research in 
medication- related experiences of multimorbid patients 
with polypharmacy.
One important aspect of synthesis 2 is the potential 
facilitating role that patients’ social network can play in 
medication adherence. This finding of social support 
being important to ensuring proper medication use is 
consistent with previous findings.10 Also, experiencing a 
lack of understanding from others about one’s condition 
negatively affected patients’ beliefs about medications.10 
This calls for healthcare professionals to include patients’ 
support networks in consultations or communicate with 
friends and relatives providing social support to ensure 
they understand the necessity for treatment and conse-
quences of non- adherence.
A finding central to our synthesis is the challenges that 
patients with polypharmacy experience in the relation-
ship with healthcare professionals. These relationships 
are challenged by multiple factors, such as power imbal-
ances, varying levels of trust, problems in interacting with 
providers or in receiving care, and conflicting advice. 
Schiøtz et al13 reported that patients with polyphar-
macy in a Danish context generally trusted healthcare 
professionals. In general, this finding was reflected in 
the included studies. However, blind trust may prevent 
patients from asking questions and disclosing important 
information relevant to their condition. Rather than 
focusing on establishing trust between patients and health-
care professionals as a means of improving adherence, 
it may be more important to address power imbalances 
and to increase continuity of care for patients, particu-
larly relational continuity, defined as ‘an ongoing ther-
apeutic relationship between a patient and one or more 
providers’.41 Mohammed et al10 found a link between 
the lack of an established relationship with healthcare 
professionals and both inappropriate medication- related 
behaviour and a negative attitude towards treatment. A 
larger treatment burden and more complex regimen 
involving multiple healthcare professionals may increase 
the risk that patients have no established patient–health-
care professional relationship. In addition, Mohammed 
et al10 argue that healthcare professionals should direct 
their attention towards patients’ lived experiences with 
medications; a focus on patients’ medication- related 
needs can lead to improvements in medication therapy 
and health outcomes. Thus, healthcare professionals must 
focus on medication- related experiences of patients with 
polypharmacy to address experiences or attitudes that 
can affect medication adherence. In a qualitative study of 
barriers to providing medication reviews for multimorbid 
Table 2 Results of the quality appraisal using the CASP checklist for qualitative studies
Item
Studies reporting the 
item, n (%) References
Was there a clear statement of the aims of the research? 13 (100) 28–40
Is a qualitative methodology appropriate? 13 (100) 28–40
Was the research design appropriate to address the aims of the research? 10 (76.9) 28 29 31–35 38–40
Was the recruitment strategy appropriate to the aims of the research? 12 (92.3) 28–30 32–40
Were the data collected in a way that addressed the research issue? 12 (92.3) 28–35 37–40
Has the relationship between researcher and participants been adequately 
considered?
0 (0) –
Have ethical issues been taken into consideration? 12 (92.3) 28–35 37–40
Was the data analysis sufficiently rigorous? 12 (92.3) 28–30 32–40
Is there a clear statement of findings? 13 (100) 28–40
How valuable is the research? 13 (100) 28–40
CASP, Critical Appraisal Skills Programme.
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• Category 1: It is hard for patients with polypharmacy to understand 
and balance harms and benefits of medications.
• Category 2: Patients with polypharmacy have different needs for 
information. However, patients need health professionals to provide 
information when regimens are changed.
Synthesis 1
Even though it is generally difficult for 
patients with polypharmacy to 
understand information about harms and 
benefits of medications, patients with 
polypharmacy are a heterogeneous group 
in terms of needing and appraising 
information and respond differently to 
the same information.
• Category 3: Adherence is highly affected by practical issues.
• Category 4: Routines are critical but can be difficult to maintain. 
Support from aids or reminders, family, and/or healthcare 
professionals can facilitate adherence.
• Category 5: All medications are not equally important to patients.
• Category 6: Patients are aware of the importance of adherence, yet 
deliberately skip or alter and forget doses.
Synthesis 2
Patients are aware of the importance of 
adherence and of developing routines for 
taking medications. However, doing so 
requires substantial effort due to 
practical issues, regimen changes, and 
skipping, altering, or forgetting doses, 
which may occur when patients assign 
different priorities to medications. 
Health professionals and patients’ social 
networks can facilitate medication 
adherence.
• Category 7: Various factors affect decision-making about 
medications, even though a single factor is often dominant. 
Maintaining or improving physical function appears to be the 
most central treatment goal for patients above other factors, such 
as extending life.
• Category 8: Patients want to reduce the number of medications, 
while also wanting the beneficial effects of medications.
• Category 9: A stable regimen is important to patients, and this 
sometimes reduces their willingness to have their medication 
regimen altered and to even discuss deprescribing with 
prescribers. However, this can be a result of the medications 
working well for the patient.
Synthesis 3
Generally, patients want to take fewer 
medications. A multitude of factors affect 
patients’ decision-making about medica-
tions, but physical function and the pref-
erence for a stable regimen are central. 
The desire for a stable regimen can even 
impact patients’ willingness to discuss 
deprescribing.
• Category 10: The healthcare professional, the doctor in 
particular, is very important to patients, but trust in doctors can 
also hinder open communication, by patients keeping from 
asking about important information.
• Category 11: The unequal power dynamics between patients and 
doctors can affect communication. Some patients compensate by 
preparing before a consultation, for example by seeking 
information. 
• Category 12: Patients make changes to their regimens without 
disclosing it to healthcare professionals. Withholding 
information can be related to the relationship with the healthcare 
professional. 
• Category 13: Physicians provide conflicting advice to patients.
• Category 14: Patients experience problems in interacting with 
providers or in receiving care, and insufficient time with 
healthcare professionals when seeking care. Continuity of care is 
important to patients. 
Synthesis 4
Multiple factors in relationships be-
tween patients and healthcare profes-
sionals, such as unequal power relations, 
trust or lack thereof, problems in 
interacting with providers or in receiving 
care, and conflicting advice, affect 
communication and increase the risk that 
patients will not disclose important 
information about their medication 
regimens. Continuity of care is im-
portant.
• Category 15: Medication-taking is a disruptive burden affecting 
patients’ lives and limiting spontaneity. Not having tangible effects 
of medications can lead to hopelessness. 
• Category 16: Being a multiple-medication user can be seen by 
patients as embarrassing.
• Category 17: Adverse effects have grave implications on patients’ 
lives and attitudes toward medications, and these might at times 
not be taken seriously by healthcare professionals.
Synthesis 5
The burden of polypharmacy does not 
arise solely from logistical challenges of 
organising medications and routines. 
Polypharmacy affects the self-perception 
of patients, can be seen by patients as 
embarrassing, and causes adverse effects 
that can have grave implications for 
patients’ lives and affect their attitudes 
toward medications.
Figure 2 Syntheses. The figure provides an overview of the five syntheses, along with the categories from which they are 
formed.
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patients with polypharmacy, general practitioners (GPs) 
expressed a clear need to improve information exchange 
between sectors by, for example, establishing a dialogue 
and collaboration between GPs and specialists.42 This 
pertains to the current study in that information exchange 
between sectors could improve the relationship between 
patients and healthcare professionals and, in particular, 
improve patients’ general perceptions of the healthcare 
system as a unified entity in which information is consis-
tent and shared across sectors.
The finding from synthesis 5 of the impact of polyphar-
macy on self- perception expands on previous findings. 
In a synthesis of qualitative studies of medication- taking 
in general, certain medications, such as those for mental 
health conditions, were reported as being particularly 
stigmatised, likely due to the stigma attached to mental 
illness.43 Our syntheses expand on this by suggesting that 
taking multiple medications, regardless of underlying 
conditions, can be perceived as embarrassing by patients. 
This feeling can affect how patients perceive and make 
decisions about taking medications and may affect adher-
ence negatively. Therefore, we see a clear need to target 
the perception of medications among patients and their 
social network to increase the adherence and quality of 
life for patients with polypharmacy.
In assessing study strengths and limitations, four eval-
uation criteria for qualitative research are relevant: 
credibility, transferability, dependability and confirma-
bility.44 The credibility of our categories and syntheses is 
enhanced by our triangulation of findings from different 
studies and transparent report. However, the transfer-
ability of our findings to all patients taking more than 
four medications is unknown. We included 13 studies 
with participants who varied in terms of the number and 
types of their medications and diagnoses and the health-
care systems in which they received care, which may limit 
transferability to some degree. However, our use of four 
or more medications as the definition of polypharmacy 
arose from our aim to capture a broad range of patient 
experiences of polypharmacy; this definition was applied 
in 4 of the 13 included studies. We did not use the most 
common definition of polypharmacy,2 but we believe 
our findings express common experiences of people 
with multimorbidity and polypharmacy. Our findings are 
dependable because we assessed the credibility of each 
finding from all papers; we are confident that our find-
ings are supported by the original data. In addition, the 
transparency of our reporting (online supplemental file 
1) allows the reader to assess how well our syntheses are 
supported by the findings. However, as is the case with all 
qualitative methods, the subjective nature of our analysis 
introduces a risk of bias. A factor potentially limiting the 
confirmability of our study is that the involved researchers 
influence the process of extracting and grouping data, 
and a single author completed data extraction. However, 
problems, doubts and unclear texts were discussed with 
the author group, and two authors collaborated in the 
data synthesis. Other factors mitigating bias include 
transparency in reporting, triangulation and assessing 
our findings in light of what was previously known. Addi-
tional strengths are our stringent process of selecting 
and appraising studies with a preplanned and structured 
approach to searching and appraising literature, the use 
of two reviewers for the screening and quality appraisal, 
and the use of CASP checklist for assessing the method-
ological quality of included studies.
CONCLUSION
Polypharmacy has a range of consequences and poses 
many challenges to patients. We identified five syntheses 
emphasising themes of central importance for patients 
with multimorbidity and polypharmacy relating to medi-
cation information needs, adherence, decision- making, 
the relationship between healthcare professionals and 
patients, and patients’ self- perception. These themes 
can affect adherence and quality of life, and it is there-
fore essential that healthcare professionals actively solicit 
individual patients’ perspectives on challenges related 
to polypharmacy. Based on the reported experiences, 
we recommend that healthcare professionals upscale 
communicative efforts and involvement of patients’ social 
network on an individualised basis to facilitate shared 
decision- making and treatment adherence in many 
patients with multimorbidity and polypharmacy.
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